Privium Fund Management B.V. / RARE
Privium Fund Management B.V.’s Ultragenyx Pharmaceutical In Position
Does Privium Fund Management B.V. own Ultragenyx Pharmaceutical In (RARE)? Yes — 364.8K shares worth $8M (+1.59% of its 13F portfolio) as of Q1 2026, up from 357.5K shares the prior filed quarter.
Position Value
$8M
Q1 2026
Shares
364.8K
% of Portfolio
+1.59%
Quarters Held
18
currently held
Position History RARE
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 364.8K | $8M | +1.59% |
| Q4 2025 | 357.5K | $8M | +1.51% |
| Q3 2025 | 289.8K | $9M | +1.57% |
| Q2 2025 | 253.3K | $9M | +1.98% |
| Q1 2025 | 249.8K | $9M | +2.36% |
| Q4 2024 | 258.4K | $11M | +2.46% |
| Q3 2024 | 242.5K | $13M | +3.35% |
| Q2 2024 | 251.6K | $10M | +2.63% |
| Q1 2024 | 215.1K | $10M | +2.68% |
| Q4 2023 | 166.5K | $8M | +2.23% |
| Q3 2023 | 115.2K | $4M | +1.22% |
| Q2 2023 | 112.2K | $5M | +1.51% |
| Q1 2023 | 110.7K | $4M | +1.49% |
| Q4 2022 | 106.7K | $5M | +1.83% |
| Q3 2022 | 82.3K | $3M | +1.21% |
| Q2 2022 | 104.9K | $6M | +2.07% |
| Q1 2022 | 112.7K | $8M | +1.81% |
| Q4 2021 | 101.8K | $9M | +1.70% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Privium Fund Management B.V.’s full portfolio or all institutional holders of RARE.